We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The HHS inspector general’s office laid out its agenda for the fiscal year, planning new and expanded reviews of the FDA’s oversight of blood establishments and laboratory-developed diagnostics; management of IT modernization initiatives; and its use of prescription drug user fees. Read More
The FDA is revising the list of drug products that have been banned or removed from the market for safety or effectiveness reasons and so cannot be used in compounding. Read More
Industry proposals to loosen regulations on off-label communication neglect to provide a comprehensive framework for the FDA to monitor unapproved uses, leaving the agency to wonder where boundaries should be drawn. Read More